Year1
- 1：
- 4
- 1：
- 5
- 2：
- 6
. -
Detailed explanation of annual survival
. At the beginning of the article, the patient talked about annual survival, which is also a language commonly used by clinicians. However, patients and their families must understand that statistical data are only averages based on a large number of cases. The statistical data on the prognosis of various types of lung cancer collected by doctors are only rough estimates of your disease and treatment results. This doesn't mean you'll survive, it just represents the proportion of people in the study who were still alive years after being diagnosed with lung cancer.
. Clinicians track the situation in the years after treatment in any study. This is because many tumors are very unlikely to relapse if they do not recur after a few years. However, lung cancer is different from other tumors in that it often Recurred later in the year. However, the current clinical statistics and follow-up of lung cancer still use years as the standard.
. In addition: According to clinical statistics and drug delivery, there are many lung cancer patients who have survived for more than 10 years, 20 years or even 20 years with the tumor. Therefore, the annual survival period is not the maximum number of years that lung cancer patients can live, it is just a big data statistic.
. - The survival time of lung cancer patients cannot be accurately judged
. Statistics cannot predict the specific situation of any individual, because each patient's lung cancer is unique, and no two cases in the world are exactly the same. The response to treatment also varies widely. The growth rate and results of the same lung cancer are different in different people. Statistics cannot tell you in detail the impact of different treatments on the prognosis. This is also the main reason why some doctors assert based on experience that a lung cancer patient can live for three months, but in fact the patient is still alive after one year.
. Patients and their families must understand and face the obvious characteristics of lung cancer uncertainty. This uncertainty means that no one can tell patients exactly what will happen to them in the next few years, and doctors cannot There is no way to tell you whose treatment is truly successful and whose treatment is bound to relapse.
. - Early detection and early treatment are the golden rules for prolonging survival
. Surgery, chemotherapy, radiotherapy, and targeted therapy may prolong life and improve symptoms. When you adapt to the treatment, the effect will be better. . However, it should be noted that there are many factors that affect the treatment and prognosis of patients. Of course, the statistical analysis of survival rate is closely related to the stage of the patient at the time of treatment. In principle, it can only be said that the earlier the discovery, the better the chance of successful treatment. big.
. Surgical treatment is for relatively early-stage lung cancer. Strictly control the surgical indications and complete tumor resection should have better results. However, clinical examples can also be seen of short-term recurrence of early-stage cancer and longer survival of late-stage cancer.
. Targeted drugs Iressa and Tarceva are conservative treatment options for advanced lung cancer, mainly to prolong the survival of patients. Of course, there are also problems with drug resistance. However, the British AstraZeneca will launch the third generation of targeted drugs at the end of this year. According to the clinical data released by AstraZeneca, the results are excellent.
. - Lung cancer survival time in clinical statistics
. The prognosis of lung cancer is closely related to the stage and pathological type during treatment. The prognosis of small cell lung cancer and non-small cell lung cancer is very different. The following are clinical statistics Lung cancer survival data.
. 1. Small cell lung cancer:
. Without treatment, patients can only survive for a few weeks.
. Limitations-diagnosis is 1/3, and the annual survival rate of chemotherapy is 3 to 3.
. Extensive-accounting for 3/3 at diagnosis, most survive to 3 months after chemotherapy.
. 2. Non-small cell lung cancer:
. Annual survival rate of stage surgery.
. Period: The annual survival rate of surgery is up to.
. Stage: Depending on how it is treated, in some stages where there is still a chance of surgery, the annual survival rate of minimally invasive disease is 3 to 3. In the more advanced stages, those with mediastinal or cervical lymph node metastasis can only receive chemotherapy.
. Stage: If the patient is diagnosed at an advanced stage, chemotherapy, conservative treatment (oral targeted drug Iressa or Tarceva) or other comprehensive treatments will be the main treatment. The annual survival rate will be 3, and the annual survival rate will be 3. Rate.
WhatsApp
